Kugurisha bishyushye Byiza CAS 78-96-6 99% Amino-2-Propanol / Isopropanolamine / Monoisopropanolamine (MIPA)

Twama nantaryo twizera ko imico yumuntu igena ibicuruzwa 'ubuziranenge, ibisobanuro bihitamo ibicuruzwa' ubuziranenge, hamwe na REALISTIC, EFFICIENT NA INNOVATIVE abakozi bo mumashanyarazi yo kugurisha ashyushye cyane CAS 78-96-6 99% Amino-2-Propanol / Isopropanolamine / Monoisopropanolamine (MIPA), Tugiye kurushaho kugerageza gufasha abaguzi bo mu gihugu ndetse n’amahanga, kandi tubyare inyungu n’ubufatanye hagati yacu.dutegereje cyane ubufatanye bwawe buvuye ku mutima.
Twama twizera ko imico yumuntu igena ibicuruzwa 'ubuziranenge, ibisobanuro bihitamo ibicuruzwa' ubuziranenge, hamwe na REALISTIC, EFFICIENT NA INNOVATIVE umwuka wabakoziUbushinwa Mipa na Monoisopropanolamine, Duhuza ibishushanyo, gukora no kohereza hanze hamwe nabakozi barenga 100 bafite ubuhanga, sisitemu yo kugenzura ubuziranenge hamwe nikoranabuhanga rifite uburambe.Tugumana umubano muremure wubucuruzi nabacuruzi hamwe nababigurisha bagize ibihugu birenga 50, nka USA, Ubwongereza, Kanada, Uburayi na Afurika n'ibindi

3′-Amino-2′-hydroxy- [1,1'-bipheny] -3-karubasi ya acide ikoreshwa nka interineti ya Eltrombopag.
Eltrombopag, yakozwe na GlaxoSmithKline (GSK) mu Bwongereza nyuma iza gukorana na Novartis mu Busuwisi, ni yo ya mbere kandi yemewe ya molekile ntoya itari peptide TPO yakira agonist ku isi.Eltrombopag yemejwe na FDA yo muri Amerika muri 2008 kugirango ivure idiopathic trombocytopenic purpura (ITP), naho muri 2014 yo kuvura anemia ikabije (AA).Ninumuti wambere wemejwe na FDA yo muri Amerika kuvura AA mumyaka 30 ishize.
Ukuboza2012, FDA yo muri Amerika yemeye Eltrombopag kuvura trombocytopenia ku barwayi barwaye hepatite C idakira (CHC), ku buryo abarwayi ba hepatite C bafite uburwayi buke buterwa na platine nkeya bashobora gutangira kandi bagakomeza kuvura bisanzwe bishingiye ku ndwara z’umwijima.Ku ya 3 Gashyantare 2014, GlaxoSmithKline yatangaje ko FDA yatanze impamyabumenyi y’ubuvuzi ya Eltrombopag yo kuvura indwara ya hémopenia ku barwayi bafite imiti ikaze y’imiti idakira (SAA) ititabira byimazeyo ubudahangarwa bw'umubiri.Ku ya 24 Kanama 2015, FDA yo muri Amerika yemeje Eltrombopag kuvura trombocytopenia ku bantu bakuru ndetse n’abana bafite imyaka 1 n’imyaka irenga hamwe na immunite trombocytopenia idakira (ITP) badafite ibisubizo bidahagije kuri corticosteroide, immunoglobuline cyangwa splenectomy.Ku ya 4 Mutarama 2018, Eltrombopag yemerewe gushyirwa ku rutonde mu Bushinwa kugira ngo ivurwe mbere na mbere na trombocytopenia (ITP).

Twama nantaryo twizera ko imico yumuntu igena ibicuruzwa 'ubuziranenge, ibisobanuro bihitamo ibicuruzwa' ubuziranenge, hamwe na REALISTIC, EFFICIENT NA INNOVATIVE abakozi bo mumashanyarazi yo kugurisha ashyushye cyane CAS 78-96-6 99% Amino-2-Propanol / Isopropanolamine / Monoisopropanolamine (MIPA), Tugiye kurushaho kugerageza gufasha abaguzi bo mu gihugu ndetse n’amahanga, kandi tubyare inyungu n’ubufatanye hagati yacu.dutegereje cyane ubufatanye bwawe buvuye ku mutima.
Kugurisha bishyushyeUbushinwa Mipa na Monoisopropanolamine, Duhuza ibishushanyo, gukora no kohereza hanze hamwe nabakozi barenga 100 bafite ubuhanga, sisitemu yo kugenzura ubuziranenge hamwe nikoranabuhanga rifite uburambe.Tugumana umubano muremure wubucuruzi nabacuruzi hamwe nababigurisha bagize ibihugu birenga 50, nka USA, Ubwongereza, Kanada, Uburayi na Afurika n'ibindi